Replies to post #164592 on Biotech Values

[jellybean]

Yes, CC-292 obtained from their purchase of Avila. http://www.celgene.com/pdfs/2011_ASH_AVL-292.pdf

Like Ibrutinib, the drug covalently attaches to C481 of the BTK binding pocket and has an IC50 of <0.5 nm, so highly specific. The drug has very low affinity for other kinases with cysteine in their binding pockets. On paper, the two drugs look very similar.